- Home
- COEP vs AKTX Comparison
COEP vs AKTX Comparison
Compare COEP & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- AKTX
- Stock Information
- Founded
- COEP 2017
- AKTX N/A
- Country
- COEP United States
- AKTX United States
- Employees
- COEP N/A
- AKTX N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- AKTX Health Care
- Exchange
- COEP Nasdaq
- AKTX Nasdaq
- Market Cap
- COEP 32.0M
- AKTX 41.8M
- IPO Year
- COEP N/A
- AKTX N/A
- Fundamental
- Price
- COEP $7.41
- AKTX $1.16
- Analyst Decision
- COEP
- AKTX
- Analyst Count
- COEP 0
- AKTX 0
- Target Price
- COEP N/A
- AKTX N/A
- AVG Volume (30 Days)
- COEP 30.9K
- AKTX 28.0K
- Earning Date
- COEP 08-15-2025
- AKTX 08-18-2025
- Dividend Yield
- COEP N/A
- AKTX N/A
- EPS Growth
- COEP N/A
- AKTX N/A
- EPS
- COEP N/A
- AKTX N/A
- Revenue
- COEP $62,874.00
- AKTX N/A
- Revenue This Year
- COEP N/A
- AKTX N/A
- Revenue Next Year
- COEP N/A
- AKTX N/A
- P/E Ratio
- COEP N/A
- AKTX N/A
- Revenue Growth
- COEP N/A
- AKTX N/A
- 52 Week Low
- COEP $2.31
- AKTX $0.85
- 52 Week High
- COEP $13.70
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- COEP 39.49
- AKTX 44.02
- Support Level
- COEP $7.21
- AKTX $1.15
- Resistance Level
- COEP $8.86
- AKTX $1.22
- Average True Range (ATR)
- COEP 0.60
- AKTX 0.07
- MACD
- COEP -0.02
- AKTX 0.00
- Stochastic Oscillator
- COEP 34.55
- AKTX 36.53
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.